Rituximab-based treatment, HCV replication, and hepatic flares

Area of Science:

• Immunology
• Oncology
• Hepatology

Background:

• Rituximab, a CD20-targeting monoclonal antibody, depletes B-cells and is used for hematologic malignancies and autoimmune diseases.
• Rituximab therapy is associated with increased replication of various viruses, including hepatitis C virus (HCV).
• HCV reactivation and hepatic flares are potential risks during or after rituximab-based chemotherapy, particularly R-CHOP.

Purpose of the Study:

• To investigate the occurrence of HCV reactivation and associated hepatic flares in patients undergoing rituximab-based chemotherapy for oncohaematological diseases.
• To assess the clinical significance and potential severity of rituximab-induced HCV flares.

Main Methods:

• Review of existing literature and small studies focusing on patients receiving R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone).
• Analysis of reported cases of HCV reactivation and hepatic flares in this patient population.

Main Results:

• Rituximab-based chemotherapy can increase HCV expression in hepatic cells.
• HCV reactivation and hepatic flares following rituximab treatment are frequently asymptomatic.
• A significant proportion (nearly 10%) of patients experiencing these flares develop life-threatening liver failure.

Conclusions:

• Rituximab therapy carries a risk of HCV reactivation and potentially severe hepatic flares in patients with hematologic malignancies.
• Close monitoring for liver function is crucial in patients receiving rituximab, especially those with a history of HCV.
• The risk of severe liver complications necessitates careful consideration of treatment strategies and patient selection.